{"disease":{"id":"gastrointestinal-stromal-tumor-gist","name":"gastrointestinal stromal tumor gist"},"drugs":{"marketed":[{"drug_id":"sunitinib","indication_name":"Gastrointestinal Stromal Tumor (GIST)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sutent","generic_name":"sunitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-phosphoinositide-dependent protein kinase 1","drug_class":"Moderate Risk QT Prolonging Agents","quality_score":67,"revenue":null,"mechanism":"Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor that inhibits PDGFRα, PDGFRβ, VEGFR1, VEGFR2, and KIT."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07072143","title":"An International Study on Pediatric Patients With Rare Tumors.","phase":"","overall_status":"RECRUITING","enrollment_count":6250,"lead_sponsor_name":"Azienda Ospedaliera di Padova","has_results":false},{"nct_id":"NCT04557969","title":"Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05489237","title":"First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":278,"lead_sponsor_name":"IDRX, Inc., a wholly owned subsidiary of GSK, LLC","has_results":false},{"nct_id":"NCT03114319","title":"Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":227,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07411118","title":"RCT of EFTR Versus STER for GIST Treatment","phase":"NA","overall_status":"RECRUITING","enrollment_count":136,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT04633122","title":"A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":108,"lead_sponsor_name":"Zai Lab (Shanghai) Co., Ltd.","has_results":true},{"nct_id":"NCT06772233","title":"A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT03404076","title":"Unifying Advanced Treatment With Advanced Imaging","phase":"","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"Heidelberg University","has_results":false},{"nct_id":"NCT00867113","title":"Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02452424","title":"A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":78,"lead_sponsor_name":"Daiichi Sankyo","has_results":true},{"nct_id":"NCT01735955","title":"Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02712112","title":"A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT05160168","title":"A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":32,"lead_sponsor_name":"Theseus Pharmaceuticals","has_results":true},{"nct_id":"NCT05354388","title":"Ripretinib Combined With Surgery in Advanced GIST That Have Failed Imatinib Therapy: A Multicenter,Observational Study","phase":"","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Sichuan Provincial People's Hospital","has_results":false},{"nct_id":"NCT05453292","title":"Endoscopic Ultrasound Radiofrequency Ablation for GISTs","phase":"NA","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Instituto Ecuatoriano de Enfermedades Digestivas","has_results":false},{"nct_id":"NCT02257541","title":"BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":true},{"nct_id":"NCT04908176","title":"A Drug-drug Interaction Study of Avapritinib and Midazolam","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT03426722","title":"L-carnitine vs Placebo for the Treatment of Muscle Cramps After Imatinib in Gastrointestinal Stromal Tumors","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT03158103","title":"A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false}],"total":19},"guidelines":[{"drug_id":"sunitinib","guideline_body":"FDA label","recommendation":"Sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate.","line_of_therapy":"2L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"sunitinib","guideline_body":"FDA label","recommendation":"Sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC).","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"sunitinib","guideline_body":"FDA label","recommendation":"Sunitinib malate capsules are indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}